¡Ya estamos en ! Descubre más

RAPT Therapeutics

RAPT

Capitalización de mercado USD 1680 M

Excluida de cotización

RAPT dejó de cotizar en bolsa el 2 de marzo de 2026.

Volver al ranking

Acerca de: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Empleados: 60

Salud Biotecnología

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 0%

Negativo 0%

The Motley Fool

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges

Great Point Partners acquired 581,187 shares of RAPT Therapeutics in the fourth quarter. The quarter-end position value increased by $19.68 million due to the new position in RAPT Therapeutics.

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Zacks Investment Research

GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout

GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.

GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout

The Motley Fool

Why Rapt Therapeutics Stock Soared Today

GSK offered to buy Rapt Therapeutics for a sizable premium to its recent market value. Rapt's experimental antibody therapy could help millions of people who suffer from severe food allergies.

Why Rapt Therapeutics Stock Soared Today

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)

NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ: RAPT) in a transaction valued at $2.2 billion.

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Jan. 20, 2026 /PRNewswire/ -- Ademi LLP is investigating RAPT (NASDAQ: RAPT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Investors Business Daily

GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout

GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.

GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™